Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Integrating cancer research in Wales for an inclusive, collaborative and sustainable future

Highlighting Welsh Cancer Research

Published: 5 Oct 2016

Views: 1676

Rating:

Save

Prof John Chester - Tenovus, Cardiff, UK

Prof Chester speaks at the Highlighting Welsh Cancer Research Conference about the multi-disciplinary, multi-facility team efforts of Welsh cancer research teams, operating under the umbrella of the Wales Cancer Research Centre.

He describes the joint research of clinical and academic institutes across Wales, represented in the Wales Cancer Partnership, and introduces upcoming conferences across the UK.

Related Videos

ASCO's strategic plan for cancer care in LMICs

Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA

ASCO's strategic plan for cancer care in LMICs ( Dr Lynn Schuchter - President, American Society of Clinical Oncology (ASCO), USA )

Synthetic biology and precision medicine in blood and gynaecological cancers

Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria...

Synthetic biology and precision medicine in blood and gynaecological cancers ( Dr Mutsa Takundwa - Council for Scientific and Industrial Research, Pretoria, South Africa )

Introducing oncology to undergraduate medical and allied health sciences...

Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India

Introducing oncology to undergraduate medical and allied health sciences students ( Dr Soumitra Shankar Datta - Tata Medical Center, Kolkata, India )

Balancing innovation and Common Sense In Oncology (CSO)

Prof Richard Sullivan - King's College London, UK

Balancing innovation and Common Sense In Oncology (CSO) ( Prof Richard Sullivan - King's College London, UK )

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer

Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal

KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer ( Dr Fatima Cardoso - Champalimaud Cancer Center, Lisbon, Portugal )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK

Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

More from ecancer